Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | G6PD | P11413 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL798352 | 0.84 | CA1 (0.35) | CA1CA2CA9HTT | |
| SCHEMBL13144439 | 0.78 | — | — | |
| SCHEMBL6542838 | 0.75 | CA1 (0.31) | CA1CA2CA9 | |
| SCHEMBL4298768 | 0.75 | CA1 (0.31) | CA1CA2CA9 | |
| Flurothyl SCHEMBL120937 | 0.73 | CA1 (0.38) | CA1CA2CA9HTTALDH1A1 | |
| SCHEMBL9012527 | 0.72 | CA1 (0.33) | CA1CA2CA9HTT | |
| SCHEMBL13280244 | 0.71 | HTT (0.37) | CA1CA2CA9HTT | |
| SCHEMBL6542842 | 0.71 | HTT (0.32) | HTT | |
| SCHEMBL9149241 | 0.71 | CA1 (0.33) | CA1CA2CA9HTT | |
| SCHEMBL18628671 | 0.71 | CA1 (0.33) | CA1CA2CA9HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5301880-A | — | — | None | — | — | JP | disclosed |
| US-11876170-B2 | Rechargeable battery cell | Innolith Technology AG (CH) | 2024-01-16 | — | — | US | disclosed |
| US-20230378540-A1 | RECHARGEABLE BATTERY CELL | INNOLITH TECH AG (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230378541-A1 | RECHARGEABLE BATTERY CELL | Innolith Technology AG (CH) | 2023-11-23 | — | — | US | disclosed |
| US-11710849-B2 | SO2-based electrolyte for a rechargeable battery cell, and rechargeable battery cells | Innolith Technology AG (CH) | 2023-07-25 | — | — | US | disclosed |
| US-9644115-B2 | Fluorochemical coating composition and article treated therewith | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-05-09 | — | — | US | disclosed |
| EP-2616465-B1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2015-11-04 | — | — | EP | disclosed |
| US-20150275046-A1 | FLUOROCHEMICAL COATING COMPOSITION AND ARTICLE TREATED THEREWITH | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2015-10-01 | — | — | US | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-20140363682-A1 | SURFACE MODIFIER AND ARTICLE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| JP-H05301880-A | PHENYLBORONIC ACID DERIVATIVE AND ITS PRODUCTION | NIPPON OIL & FATS CO LTD | 1993-11-16 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | CA1 4324/4885CA2 1817/4885CA9 4303/4885 |
| US-11876170-B2 | Rechargeable battery cell | HCN1, HCN3, KCNN1 | CA1 47/4885CA2 13/4885CA9 96/4885 |
| US-11710849-B2 | SO2-based electrolyte for a rechargeable battery cell, and rechargeable battery cells | ATXN2, ARSA, ANXA11 | CA1 24/4885CA2 6/4885CA9 48/4885 |
| US-20140051676-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | CA1 4324/4885CA2 1817/4885CA9 4303/4885 |
| US-20140363682-A1 | SURFACE MODIFIER AND ARTICLE | NOTUM, UFM1, LIPA | CA1 562/4885CA2 2344/4885CA9 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.